Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R inhibitors
A. Nagle, K. M. Levine, N. Tasdemir, J. A. Scott, K. Burlbaugh, J. Kehm, T. A. Katz, D. N. Boone, B. M. Jacobsen, J. M. Atkinson, S. Oesterreich, A. V. Lee
This study shows that loss of E-cadherin increases IGF1R pathway activation and makes breast cancers more responsive to anti-IGF1R therapies.
Clinical Cancer Research · Oct 15, 2018Peer-reviewedCancer Biology